Inicio
Explorar
nav.journalClub
Tendencias
Más
synapse
⌘+K
Idioma
Español
Español
High concentration subcutaneous biological drug products: challenges and advancements | Synapse
March 3, 2026
High concentration subcutaneous biological drug products: challenges and advancements
GH
Guangli Hu
MM
Mikolaj Milewski
Merck & Co., Inc., Rahway, NJ, USA (United States)
YK
Yogita Krishnamachari
Merck & Co., Inc., Rahway, NJ, USA (United States)
Ver todo
Puntos clave
High concentration biological drugs can improve patient compliance and clinical outcomes, but present formulation challenges.
Studies show that immunogenicity may increase with higher concentrations in subcutaneous delivery, affecting efficacy.
Observational analysis of existing formulations highlights key challenges in stability and delivery mechanisms for biological drugs.
Improvements in subcutaneous delivery methods could enhance the pharmacokinetics of biological drugs, indicating robust future potential.
Mark Helpful
Me gusta
Save
Guardar
Relay
Compartir
Cite This Study
Copy
Hu et al. (Fri,) studied this question.
synapsesocial.com/papers/69a76880badf0bb9e87e4e5c
https://doi.org/https://doi.org/10.1016/j.addr.2026.115793
Mark Helpful
Me gusta
Save
Guardar
Relay
Compartir